The Competent Authority has approved the entrustment of the additional charge of the post of Director (Finance) at IRCTC to Shri Sudhir Kumar, IRAS, GGM/Finance/IRCTC. This appointment is for a period of one year, effective from July 22, 2025, or until a regular appointment is made. The decision was communicated on November 7, 2025.

Additional Charge Approval

The Ministry of Railways has communicated the approval for the additional charge of the Director (Finance) post at IRCTC. Shri Sudhir Kumar, IRAS, GGM/Finance/IRCTC, has been entrusted with this responsibility.

Tenure and Effective Date

The additional charge is effective from July 22, 2025, and will continue for a period of one year. This arrangement will remain in effect until a regular appointment is made to the post or until further orders are issued, whichever occurs earliest.

Source: BSE

Trent Limited’s board has approved tendering 94,900 equity shares held by the company in Inditex Trent Retail India Private Limited (ITRIPL) for a buyback offer. The buyback offer, dated November 5, 2025, is for shares with a face value of ₹1000 each, priced at ₹15,421.85 per share. ITRIPL is an associate company with Trent holding a 34.94% shareholding.

ITRIPL Buyback Offer

Trent Limited has announced that it has received a Letter of Offer dated November 5, 2025, concerning a buyback offer from Inditex Trent Retail India Private Limited (“ITRIPL”). Trent holds a 34.94% shareholding in ITRIPL.

Details of the Buyback

The buyback involves 94,900 Equity Shares, each with a face value of ₹1000. The offer price is ₹15,421.85 per Equity Share. This will be executed through a “tender offer” route, in compliance with the Companies Act, 2013 and associated rules.

Board Approval and Acceptance

The Board of Directors of Trent Limited met on November 7, 2025, and approved tendering the 94,900 Equity Shares held by the company in ITRIPL. The buyback is subject to acceptance by ITRIPL. The board meeting commenced at 10:00 a.m. and concluded at 4:30 p.m.

Source: BSE

Bharat Petroleum Corporation Limited (BPCL) has announced the extension of the additional charge of Chairman and Managing Director entrusted to Shri Sanjay Khanna, Director (Refineries). Effective from November 1, 2025, this extension will continue until further notice from the Ministry of Petroleum & Natural Gas, as stated in their letter dated November 7, 2025.

Directorate Update

The additional charge held by Shri Sanjay Khanna, Director (Refineries), as Chairman and Managing Director at Bharat Petroleum Corporation Limited, has been extended. This decision, effective November 1, 2025, ensures continuity in leadership.

Continued Leadership

The tenure extension for Shri Khanna will remain in effect until new directives are issued by the Ministry of Petroleum & Natural Gas. The official communication regarding this extension is dated November 7, 2025.

Source: BSE

Trent Limited announces that Ms. Susanne Given will cease to be an Independent Director, effective at the close of business hours on November 16, 2025. Her departure marks the completion of her five-year term, which commenced on November 17, 2020. This announcement follows the standard procedures for director transitions within the company.

Independent Director Cessation

Trent Limited has confirmed the upcoming departure of Ms. Susanne Given from her role as an Independent Director. This change will take effect at the close of business on November 16, 2025.

Term Completion

Ms. Given’s departure is due to the completion of her full term as an Independent Director. She was initially appointed for a five-year period, beginning on November 17, 2020. The company acknowledges her service throughout her tenure.

Source: BSE

Narayana Hrudayalaya has announced the acquisition of UK-based Practice Plus Group Hospitals Limited. The investor call highlighted the strategic rationale, emphasizing the UK market’s stability and growth potential. The acquired entity operates with a 93% NHS payor mix, offering opportunities for margin improvement and private payor growth. The deal, funded through Cayman balance sheet, aims for a 20%-22% ROCE by FY29-30.

Strategic Rationale for Acquisition

Narayana Hrudayalaya’s management team, during the investor call on November 3, 2025, outlined the reasons for acquiring Practice Plus Group Hospitals Limited in the UK. The UK market offers stability, a developed economy, and a clear rule of law. The private sector plays a key role in addressing healthcare needs and the acquisition aligns with the company’s long-term growth strategy.

Key Highlights of Practice Plus Group

Practice Plus Group stands out due to its size and management. The company has a good sweet spot in terms of size. Importantly, the entire senior leadership is expected to stay with Narayana Hrudayalaya. The asset operates with a 93% NHS payor mix, marking it as an outlier. There’s a focus on improving efficiencies through technology, mirroring successful strategies implemented in Cayman.

Financial Details and Future Outlook

The acquisition is expected to be EPS neutral in the first year and mildly favorable thereafter. The post-IFRS EBITDA for FY25 is GBP 29 million. A ROCE of 20%-22% is targeted by FY29-30. The deal is funded through the Cayman balance sheet with 40 million pounds as equity. Efforts are underway to integrate Athma, the company’s tech stack.

Growth and Operational Strategies

Key strategies include attracting more private payor patients, expanding into new specialties, and implementing operational efficiencies based on the company’s technology platform. There’s potential to leverage the existing infrastructure and increase non-NHS revenue. It is expected that new services would require new doctors as the company gets more involved. The business has regular maintenance and refurbishment Capex in the GBP 10-20 million range every year.

Regulatory and Integration Aspects

The UK’s clinical regulation is robust, governed by the CQC and related bodies. All of Practice Plus Group’s assets are rated good or excellent by the CQC. Integration of technology is a journey that will begin by starting with low-hanging fruit immediately.

Financial Performance and Future Plans

The company is currently operating with 330 operational beds. Current utilization is 50-55% offering additional space for volume. Plans for near-term integration are underway. It is aimed that the company will be cash breakeven in short years. There are hopes to build on and improve margin. There is an intention is to lower the cost of self-pay care and PMI care.

Source: BSE